Cables

Moderna impulsa las esperanzas de tener una vacuna contra covid-19 en diciembre

This picture taken on November 18, 2020 shows a syringe and a bottle reading "Vaccine Covid-19" next to the Moderna biotech company logo. - The CEO of Moderna warned European countries on November 17 that dragging out negotiations to purchase its promising new Covid-19 vaccine will slow down deliveries, as other nations that have signed deals will get priority. The biotech company Pfizer said the day after that a completed study of its experimental Covid-19 vaccine showed it is 95 percent effective, after Moderna said its own vaccine was 94.5 percent effective, according to a preliminary analysis. (Photo by JOEL SAGET / AFP)
This picture taken on November 18, 2020 shows a syringe and a bottle reading "Vaccine Covid-19" next to the Moderna biotech company logo. - The CEO of Moderna warned European countries on November 17 that dragging out negotiations to purchase its promising new Covid-19 vaccine will slow down deliveries, as other nations that have signed deals will get priority. The biotech company Pfizer said the day after that a completed study of its experimental Covid-19 vaccine showed it is 95 percent effective, after Moderna said its own vaccine was 94.5 percent effective, according to a preliminary analysis. (Photo by JOEL SAGET / AFP) JOEL SAGET

Las esperanzas de una primera ola de vacunación contra el covid-19 antes del fin de 2020 recibieron un impulso de la empresa estadounidense Moderna, que dijo el lunes que estaba solicitando la autorización de emergencia de su vacuna en Estados Unidos y Europa.

Moderna informó que los resultados completos habían confirmado una alta eficacia de la vacuna, estimada en un 94,1%.

La firma se preparaba así para unirse a la estadounidense Pfizer y su socia alemana BioNTech, que la semana pasada solicitaron una aprobación similar de su vacuna y predicen que esta podría obtener luz verde en Estados Unidos después del 10 de diciembre.

‌
‌

‌

‌
‌

‌

‌